
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's financial position is robust, as the company reported approximately €16.7 billion in cash and cash equivalents, which provides significant liquidity for ongoing research and development initiatives. The incremental positive news regarding BNT323 highlights the potential for successful advancements in its oncology pipeline, particularly in the Phase 3 DYNASTY-Breast02 trial focused on breast cancer treatments. Additionally, the preclinical data showing the effectiveness of the LP.8.1-adapted COVID-19 vaccine against various circulating SARS-CoV-2 sublineages underscores the company's capacity to innovate and respond to emerging health challenges, further strengthening its market position.
Bears say
BioNTech faces substantial risks that negatively impact its stock outlook, including the potential for negative data across several key oncology drug candidates, slower-than-expected market uptake, and challenges in advancing programs on schedule. The company's financial performance further underscores this sentiment, as it recorded a net loss per diluted share of €0.12 in Q3 2025, with projections indicating a full-year net loss per diluted share of €3.99. Additionally, evolving dynamics in the COVID-19 vaccine market, particularly influenced by new regulatory environments, may divert investor focus from the company’s oncology portfolio, heightening concerns about its operational stability and long-term viability.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares